Stem Cells in Ophthalmology Update 3: ACT Files IND to Treat Dry AMD
Furthering its lead in stem cell research in ophthalmology, Advanced Cell Technology Inc., announced today that it had filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration, to initiate a Phase I/II multicenter study for the treatment of dry Age-Related Macular Degeneration (dry AMD) using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells.